Articles On Auscann Group Holdings (ASX:AC8)

Just two years after medicinal cannabis company AusCann (ASX: AC8) acquired CannPal Animal Therapeutics in a scrip-based deal worth $17.5 million at the time, the group has today announced it will be divesting 52 per cent of its stake in th...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

AusCann Group’s(AC8) Chief Executive Officer announces his resignationAfter one and a half years with the company, Layton Mills tendered his resignation to the board, citing his desire to pursue other business interestsMr Mills says he will...

Actor and cannabis farmer Jim Belushi is headlining the Grow Up Conference and Expo next month Franchise Global Health has established the first legal seedbank in Denmark Botanix nabs FDA Qualified Infection Disease Product designation for...

AusCann (AC8) enters a binding term sheet with European Cannabis Corporation (Eurocann) to expand into the European cannabis market Under the term sheet, the companies will work together to establish a joint steering committee to focus on...

AusCann (AC8) receives its official Memorandum of Conference (MoC) from the US Food and Drug Administration Centre for Veterinary Centre (US FDA-CVM) The MoC follows a successful meeting which was held in December last year to discuss the...

The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product sales estimated at $230 million. And medical cannabis prescriptions are at an all-time high. The TGA said 13,666 Australian patients were app...

AusCann (AC8) submits its final regulatory data modules to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for DermaCann The data in the modules includes findings from a randomised, placebo-controlled study in dogs wit...

The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%. Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of i...

The ASX had a positive finish to the week although it is in negative territory for the week. The ASX 200 closed at 7,443 points which is up 0.83% from yesterday but slightly down from the 7,457 mark it closed at last Friday. Today, the only...

AusCann Group (AC8) begins designing a clinical discovery trial to evaluate its cannabinoid-based formulation in people with spinal cord injury (SCI) Spinal cord injury occurs when there is damage to any part of the spinal cord or nerves a...

Australian medicinal cannabis company AusCann (ASX: AC8) today announced it is preparing a trial of its proprietary cannabinoid-based formulations in people with spinal cord injury (SCI). The company, which acquired CannPal Animal Therapeu...

The ASX 200 Health Index (XHJ) is down by 2.2% at the time of writing, compared to the broader index which is down by 0.60%. AusCann Group (ASX:AC8) is about to commence an exploratory cannabinoid (CBD) trial in people with spinal cord inju...

Actor Jim Belushi has partnered with – you guessed it – Dan Aykroyd on a tour through Oklahoma’s cannabis industry ahead of a Blues Brothers performance. “We believe that cannabis is one of the great, great medicines that can lead to a path...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

The ASX Health Care index (XHJ) was down by 0.11% this morning, compared with the broader ASX 200 index which fell by more than 1% at the time of writing. Medicinal cannabis company, Epsilon Healthcare (ASX:EPN), jumped by 20% out of the bl...

Wall Street drifts lower on economic concerns All three major US stock market indexes slipped for the second consecutive day overnight, as investors weigh recent economics data and risk factors. The Dow Jones fell by 0.20%, the S&P 500...

As more and more ASX stocks file their quarterlies, the list of the best performers looks somewhat different this afternoon than what it did this morning. Stockhead has recapped the latest changes:   Applyflow (ASX:AFW) The HR tech stock on...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

The S&P/ASX200 is lower today, dropping 50.90 points or 0.70% to 7,235.10 and setting a new 20-day low. The index has lost 1.32% for the last five days, but sits 2.31% below its 52-week high. Sectors are mixed. 9 of 11 sectors are lowe...

Summary The S&P/ASX200 opened lower and declined as much as 1.1% to hit a low of 7,205. The index was down just 0.12% by the lunchtime, supported by gains in health care and tech stocks. Seven of 11 sectors were floating in red, w...

Key Highlights AusCann has submitted its first module to the Australian Pesticides and Veterinary Medicines Association (APVMA) to commence the submission of its dossier for the registration of DermaCann®, in development for anti-inflam...

The ASX Healthcare index rose by 0.45% this morning, compared with the broader index which fell by 0.80%, helped by medicinal cannabis company AusCann (ASX:AC8). It rose by 5% in morning trading. AusCann announced it has submitted the first...

This week Technicorum Holdings announced an upcoming token sale and launch of The CanCoin – a cannabis token designed to solve market friction and monetisation in the European cannabis market and to help build blockchain-based solutions for...

The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t...

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

Summary The S&P/ASX200 closes Thursday session a tad bit lower, dropped 0.37%. eCargo posts gains on partnership with NZ's Fonterra unit Seven West Media shares rises on strong FY21 forecast The S&P/ASX200 closed lower Thu...

Summary The ASX 200 ends 27.20 points or 0.37% lower at 7,359. Seven out of 11 sectors ended in red, while telecom and energy emerging as the worst performer. The market sentiment was dented as US Federal Reserve indicated a rate hike...

S&P 500 nears record high again on prospect of US$1.8 trillion government spend All the major indices in the US rose, after President Biden’s speech to Congress in which he spoke about a new US$1.8 trillion family aid plan. The plan wil...

Source: Yarygin, Shutterstock Summary The Australian cannabis market is flourishing with growing patient numbers and better product selection. Medicinal cannabis player Bod Australia has won a new PO for CBD products for the US cannab...

Small caps have dipped slightly, while their larger peers have gained. The Small Ordinaries index fell 2.6 points on Monday, or 0.08 per cent, to 3,195.6, while the ASX100 gained 0.73 per cent and the All Ordinaries gained 0.51 per cent. Th...

Source:ElRoi, Shutterstock Summary Cann Group is a $163.9 billion cannabis company focused on breeding, cultivating, manufacturing and supplying medicinal cannabis. AusCann Group is the smallest cannabis player in this list, with a ma...

The ASX saw the best IPO debut of the year to date in manganese explorer Firebird Metals (ASX:FRB), which rose 198 per cent on debut. This beat the previous 2021 record held by WA telco Pentanet (ASX:5GG), which finished its first day in la...

CannPal Animal Therapeutics (ASX: CP1) shareholders voted overwhelmingly in favour of allowing cannabis company AusCann (ASX: AC8) to acquire the company for $17.5 million at a meeting yesterday. If the Supreme Court of Western Australia...

Summary With COVID-19 giving the opportunity to develop products, enhance services and conduct R&D, healthcare sector will be vigilantly gauged. Early spotting of a winning penny stock can offer considerable rewards to patient and...

Layton Mills' company CannPal Animal Therapeutics (ASX: CP1) may be the target in a scrip-based acquisition from medicinal cannabis industry peer AusCann Group (ASX: AC8), but that doesn't mean he'll be cashing in and walking out the door w...

  Summary AusCann Group to change its CEO after completing the acquisition of the animal health company, CannPal Animal Therapeutics Limited. Nick Woolf, CEO AusCann, agreed to tender his resignation but decided to work as Interim CEO t...

The AusCann Group Holdings Ltd (ASX: AC8) share price is on the move on Friday after the release of an announcement. In morning trade the medicinal cannabis company’s shares are up 14% to 24 cents. What did AusCann announce? This morning A...

Investors in ASX cannabis shares have had a bumpy ride in 2020. Share prices were impacted by global oversupply issues in late 2019 then plunged in the March 2020 market downturn. But the Australian medical marijuana industry is building...

Marijuana companies – or “pot stocks” to those who prefer brevity – were all the rage back in late 2017 and early 2018. California, America’s most populous state and the fifth largest economy in the world, was legalising the recreational u...

The Elixinol Global Ltd (ASX: EXL) share price tumbled after management issued an update to its share purchase plan (SPP) today. The EXL share price lost 7.6% to 24 cents in after lunch trade when the S&P/ASX 200 Index (Index:^AXJO) ga...

Cannabis and its derivatives are on their way to being more widely recognised for their medicinal and therapeutic benefits following the drug’s reclassification this week as a non-narcotic. The most widely-used illicit drug lost its status...

The CannPal Animal Therapeutics Ltd (ASX: CP1) share price is shooting higher today, rising 20% to 15 cents per share. The CannPal share price closed at 12 cents a share last Friday after the company was placed in a trading halt. CannPal o...

The Auscann Group Holdings Ltd (ASX: AC8) and Cannpal Animal Therapeutics Ltd (ASX: CP1) share prices will be on watch tomorrow. (Assuming, of course, that the ASX system has returned to functionality by then!) Both companies entered a tra...

Australian Pharmaceutical company AusCann Group Holdings Ltd (ASX:AC8) has entered a scheme implementation deed with CannPal Animal Therapeutics Limited to acquire 100% issued share capital of CannPal. Under the terms of the Scheme Impleme...

Special Report: CannPal Animal Therapeutics (ASX:CP1) has entered into a scheme implementation deed with AusCann Group Holdings (ASX:AC8), agreeing to ... Read More The post A ‘game-changing’ cannabis merger: AusCann buys their way into the...

Two major ASX-listed medicinal cannabis companies could soon be under one roof after the board of CannPal Animal Therapeutics (ASX: CP1) agreed to a scrip-based buyout from AusCann Group (ASX: AC8). If the deal goes ahead CannPal investor...

The Auscann Group Holdings Ltd (ASX: AC8) share price has been on the move today following the sale of its DayaCann holdings. When the news broke, shares in the cannabinoid pharmaceutical company rose to 15 cents, however they have since r...

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

The marijuana business is slowly, but inexorably, moving from the world’s black markets onto global share markets. During the initial round of exuberance, as Canada and some of the biggest states in the US legalised not just marijuana’s me...